These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 27372285)

  • 1. Performance of a phosphoflow assay to determine phosphorylation of S6 ribosomal protein as a pharmacodynamic read out for mTOR inhibition.
    Abdel-Kahaar E; Kabakchiev M; Hartmann B; Wieland E; Shipkova M
    Clin Biochem; 2016 Oct; 49(15):1181-1187. PubMed ID: 27372285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamic monitoring of mammalian target of rapamycin inhibition by phosphoflow cytometric determination of p70S6 kinase activity.
    Hoerning A; Wilde B; Wang J; Tebbe B; Jing L; Wang X; Jian F; Zhu J; Dolff S; Kribben A; Hoyer PF; Witzke O
    Transplantation; 2015 Jan; 99(1):210-9. PubMed ID: 25099702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assay validation of phosphorylated S6 ribosomal protein for a pharmacodynamic monitoring of mTOR-inhibitors in peripheral human blood.
    Dieterlen MT; Bittner HB; Klein S; von Salisch S; Mittag A; Tárnok A; Dhein S; Mohr FW; Barten MJ
    Cytometry B Clin Cytom; 2012 May; 82(3):151-7. PubMed ID: 22213594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma.
    Li S; Kong Y; Si L; Chi Z; Cui C; Sheng X; Guo J
    BMC Cancer; 2014 May; 14():376. PubMed ID: 24886512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of confounding factors on a phospho-flow assay of ribosomal S6 protein for therapeutic drug monitoring of the mTOR-inhibitor everolimus in heart transplanted patients.
    Dieterlen MT; John K; Haase S; Garbade J; Tarnok A; Mohr FW; Bittner HB; Barten MJ
    Biomarkers; 2017 Feb; 22(1):86-92. PubMed ID: 27448205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of mTOR and calcineurin inhibitors combined therapy in Epstein-Barr virus positive and negative Burkitt lymphoma cells.
    Wowro SJ; Schmitt KRL; Tong G; Berger F; Schubert S
    Int Immunopharmacol; 2016 Jan; 30():9-17. PubMed ID: 26613512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamic Monitoring of mTOR Inhibitors.
    Millán O; Wieland E; Marquet P; Brunet M
    Ther Drug Monit; 2019 Apr; 41(2):160-167. PubMed ID: 30883509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a sensitive phospho-p70 S6 kinase ELISA to quantify mTOR proliferation signal inhibition.
    Hartmann B; He X; Keller F; Fischereder M; Guba M; Schmid H
    Ther Drug Monit; 2013 Apr; 35(2):233-9. PubMed ID: 23503450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. P70S6 kinase phosphorylation: a new site to assess pharmacodynamy of sirolimus.
    Wang JY; Fan H
    Chin Med J (Engl); 2015 Mar; 128(5):664-9. PubMed ID: 25698201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Everolimus-treated renal transplant recipients have a more robust CMV-specific CD8+ T-cell response compared with cyclosporine- or mycophenolate-treated patients.
    Havenith SH; Yong SL; van Donselaar-van der Pant KA; van Lier RA; ten Berge IJ; Bemelman FJ
    Transplantation; 2013 Jan; 95(1):184-91. PubMed ID: 23222818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The ribosomal protein S6 in renal cell carcinoma: functional relevance and potential as biomarker.
    Knoll M; Macher-Goeppinger S; Kopitz J; Duensing S; Pahernik S; Hohenfellner M; Schirmacher P; Roth W
    Oncotarget; 2016 Jan; 7(1):418-32. PubMed ID: 26506236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Assessment of P70S6 kinase phosphorylation after liver transplantation by phospho-flow cytometry].
    Wang J; Fan H
    Zhonghua Yi Xue Za Zhi; 2014 Dec; 94(48):3809-12. PubMed ID: 25623311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 18F-FLT PET as a surrogate marker of drug efficacy during mTOR inhibition by everolimus in a preclinical cisplatin-resistant ovarian tumor model.
    Aide N; Kinross K; Cullinane C; Roselt P; Waldeck K; Neels O; Dorow D; McArthur G; Hicks RJ
    J Nucl Med; 2010 Oct; 51(10):1559-64. PubMed ID: 20847160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Target Enzyme Activity and Phosphorylation of Pathway Molecules As Specific Biomarkers in Transplantation.
    Budde K; Sommerer C; Rissling O; Dieterlen MT; Barten MJ
    Ther Drug Monit; 2016 Apr; 38 Suppl 1():S43-9. PubMed ID: 26977999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Everolimus is better than rapamycin in attenuating neuroinflammation in kainic acid-induced seizures.
    Yang MT; Lin YC; Ho WH; Liu CL; Lee WT
    J Neuroinflammation; 2017 Jan; 14(1):15. PubMed ID: 28109197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of the Akt-mTOR pathway and receptor tyrosine kinase in patients with solitary fibrous tumors.
    Yamada Y; Kohashi K; Fushimi F; Takahashi Y; Setsu N; Endo M; Yamamoto H; Tokunaga S; Iwamoto Y; Oda Y
    Cancer; 2014 Mar; 120(6):864-76. PubMed ID: 24353015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-cell pharmacodynamic monitoring of S6 ribosomal protein phosphorylation in AML blasts during a clinical trial combining the mTOR inhibitor sirolimus and intensive chemotherapy.
    Perl AE; Kasner MT; Shank D; Luger SM; Carroll M
    Clin Cancer Res; 2012 Mar; 18(6):1716-25. PubMed ID: 22167413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological targeting of mammalian target of rapamycin inhibits ovarian granulosa cell tumor growth.
    Rico C; Laguë MN; Lefèvre P; Tsoi M; Dodelet-Devillers A; Kumar V; Lapointe E; Paquet M; Nadeau MÈ; Boerboom D
    Carcinogenesis; 2012 Nov; 33(11):2283-92. PubMed ID: 22871496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unique, highly proliferative growth phenotype expressed by embryonic and neointimal smooth muscle cells is driven by constitutive Akt, mTOR, and p70S6K signaling and is actively repressed by PTEN.
    Mourani PM; Garl PJ; Wenzlau JM; Carpenter TC; Stenmark KR; Weiser-Evans MC
    Circulation; 2004 Mar; 109(10):1299-306. PubMed ID: 14993145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Everolimus halts hepatic cystogenesis in a rodent model of polycystic-liver-disease.
    Temmerman F; Chen F; Libbrecht L; Vander Elst I; Windmolders P; Feng Y; Ni Y; De Smedt H; Nevens F; van Pelt J
    World J Gastroenterol; 2017 Aug; 23(30):5499-5507. PubMed ID: 28852309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.